Repligen Corp
RGEN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000730272
In the last 90 days, Repligen Corp insiders filed 0 open-market purchases and 5 sales; 481 institutions reported holding it in 13F filings for Q2 2026, worth $9.00B in total; 3 superinvestors hold it, including Maverick Capital and Duquesne Family Office.
Q4 2022 vs. Q3 2022
How the institutions holding Repligen Corp changed between Q3 2022 and Q4 2022.
All holders in Q4 2022All holders in Q3 2022
| Measure | Q3 2022 | Of which not filed for Q4 2022 | Q4 2022 | Change |
|---|---|---|---|---|
| Holders | 434 | 6 | 443 | +15 |
| Shares | 51.0M | 120.3K | 53.5M | +2.58M (+5.1%) |
| Value | $9.56B | $22.5M | $9.06B | −$476.1M (−5.0%) |
6 institutions that held it in Q3 2022 haven't filed for Q4 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (77)
Institutions that held Repligen Corp at the end of Q4 2022 but not at the end of Q3 2022.
Sold out (62)
Institutions that held Repligen Corp at the end of Q3 2022 and filed for Q4 2022 without it.
Not filed for Q4 2022 yet (6)
Institutions that held Repligen Corp at the end of Q3 2022 and haven't filed a 13F for Q4 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2022 | Value, Q3 2022 |
|---|---|---|
| Eaton Vance Management | 102,218 | $19.1M |
| Jefferies Group LLC | 14,000 | $2.62M |
| Budros, Ruhlin & Roe, Inc. | 2,000 | $374.0K |
| American Portfolios Advisors | 1,166 | $218.2K |
| Wipfli Financial Advisors LLC, | 831 | $155.0K |
| Covington Capital Management | 50 | $9.00K |